What the review examined

A scoping review from the Department of Orthopaedic Surgery at the David Geffen School of Medicine at UCLA, reported online ahead of print in the American Journal of Sports Medicine in August 2026, set out to test a simple question: how strong is the human evidence behind six of the most heavily marketed "recovery" peptides? [1][2]

The reviewers worked through the PubMed literature under PRISMA guidance, pairing six compounds — BPC-157, TB-500, CJC-1295, MK-677 (ibutamoren), ipamorelin and GHK-Cu — with musculoskeletal tissue and performance terms. UCLA's newsroom puts the number of studies assessed at 565, spanning animal and human models. [1][2]

What it found

The headline is not that the compounds do nothing, but that the evidence is thinner and weaker than the marketing implies. [1][2]

  • More than two-thirds of the studies reviewed were conducted in animals. The human research that exists is limited and, on the reviewers' assessment, generally of low quality — often lacking robust controls or rigorous study design. [1]
  • There were "essentially no studies demonstrating significant clinical benefits for musculoskeletal conditions". [2]
  • Several apparently positive human results came from studies that used a topical agent with limited evidence in a skin condition and then inferred benefit for injected musculoskeletal use — a scope mismatch the authors highlight. [2]
  • One of the largest BPC-157 studies carried a conflict of interest: the group running it held a financial interest in the compound. [2]

On the totality of the evidence, the authors concluded that the claimed benefits of these peptide supplements for musculoskeletal recovery and performance remain unsubstantiated by current human trials, and that they should not currently be recommended as a replacement for — or adjunct to — existing orthopaedic standard of care. [1][2]

The safety signal the review flagged

The review also drew attention to a documented safety concern for MK-677. In a randomised, placebo-controlled Phase IIb study of MK-677 (ibutamoren mesylate) in older adults recovering from hip fracture, the trial was stopped early because of a higher rate of congestive heart failure in one treatment group. [1][3]

The UCLA team's orthopaedic author, Dr Kremen, described a clinical case in which a seemingly young, healthy patient presenting for routine rotator-cuff repair was found to have cardiac output too low to operate safely outside a hospital setting, and disclosed peptide use. He was explicit that causality could not be established. [1] A single case is hypothesis-generating, not proof of harm — but it is the kind of signal a low-quality evidence base cannot rule out.

Scope and limits

This is a scoping review, not a new trial or a pooled meta-analysis of effect sizes; its strength is in mapping the shape of a literature and its weaknesses. It addresses musculoskeletal and performance claims specifically. It does not assess the licensed GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide and others — whose large randomised-trial programmes and MHRA authorisations sit in a different evidentiary category entirely. And while the review is US-authored, the evidence question it examines is jurisdiction-neutral.

Why it matters in the UK

None of the six compounds reviewed is an MHRA-authorised medicine in the UK. Under the Human Medicines Regulations 2012, a product presented as treating a condition or modifying a bodily function is a medicinal product irrespective of a "research use only" label. The MHRA has said it disregards research-purpose claims where they are being used to avoid medicines regulation, and will act against products promoted for human use that are not licensed. [4][5]

For readers of this reference, the review reinforces the framework Peptide Data already applies: an evidence grade is a statement about the quality and human relevance of the literature, and a deep preclinical column does not substitute for human data. Where support rests overwhelmingly on animal models and uncontrolled human reports, compounds sit at Limited or Anecdotal on the four-tier scale — a position this review independently corroborates rather than overturns. [6]

Peptide Data does not provide consumption, dosing or self-administration advice for any compound. The compounds discussed here are research chemicals; nothing in this article should be read as a claim that any peptide treats, cures or prevents any condition.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.